1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of RNA-Based Therapeutics and Vaccines

1.2 Classification of RNA-Based Therapeutics and Vaccines by Type

1.2.1 Overview: Global RNA-Based Therapeutics and Vaccines Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type in 2021

1.2.3 RNA-Based Therapeutics

1.2.4 RNA-Based Vaccines

1.3 Global RNA-Based Therapeutics and Vaccines Market by Application

1.3.1 Overview: Global RNA-Based Therapeutics and Vaccines Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Oncology

1.3.3 Immunology

1.3.4 Ophthalmology

1.3.5 Cardiovascular Diseases

1.3.6 Infectious Diseases

1.3.7 Genetic Diseases

1.3.8 Others

1.4 Global RNA-Based Therapeutics and Vaccines Market Size & Forecast

1.5 Global RNA-Based Therapeutics and Vaccines Market Size and Forecast by Region

1.5.1 Global RNA-Based Therapeutics and Vaccines Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global RNA-Based Therapeutics and Vaccines Market Size by Region, (2017-2022)

1.5.3 North America RNA-Based Therapeutics and Vaccines Market Size and Prospect (2017-2028)

1.5.4 Europe RNA-Based Therapeutics and Vaccines Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size and Prospect (2017-2028)

1.5.6 South America RNA-Based Therapeutics and Vaccines Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa RNA-Based Therapeutics and Vaccines Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 RNA-Based Therapeutics and Vaccines Market Drivers

1.6.2 RNA-Based Therapeutics and Vaccines Market Restraints

1.6.3 RNA-Based Therapeutics and Vaccines Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 Alnylam Pharmaceuticals

2.1.1 Alnylam Pharmaceuticals Details

2.1.2 Alnylam Pharmaceuticals Major Business

2.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

2.1.4 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.2 Arbutus Biopharma

2.2.1 Arbutus Biopharma Details

2.2.2 Arbutus Biopharma Major Business

2.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product and Solutions

2.2.4 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Arbutus Biopharma Recent Developments and Future Plans

2.3 Arrowhead Pharmaceuticals

2.3.1 Arrowhead Pharmaceuticals Details

2.3.2 Arrowhead Pharmaceuticals Major Business

2.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

2.3.4 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Arrowhead Pharmaceuticals Recent Developments and Future Plans

2.4 BioNTech

2.4.1 BioNTech Details

2.4.2 BioNTech Major Business

2.4.3 BioNTech RNA-Based Therapeutics and Vaccines Product and Solutions

2.4.4 BioNTech RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 BioNTech Recent Developments and Future Plans

2.5 CureVac

2.5.1 CureVac Details

2.5.2 CureVac Major Business

2.5.3 CureVac RNA-Based Therapeutics and Vaccines Product and Solutions

2.5.4 CureVac RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 CureVac Recent Developments and Future Plans

2.6 Dicerna Pharmaceuticals

2.6.1 Dicerna Pharmaceuticals Details

2.6.2 Dicerna Pharmaceuticals Major Business

2.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

2.6.4 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Dicerna Pharmaceuticals Recent Developments and Future Plans

2.7 Regulus Therapeutics

2.7.1 Regulus Therapeutics Details

2.7.2 Regulus Therapeutics Major Business

2.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

2.7.4 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Regulus Therapeutics Recent Developments and Future Plans

2.8 Marina Biotech

2.8.1 Marina Biotech Details

2.8.2 Marina Biotech Major Business

2.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Product and Solutions

2.8.4 Marina Biotech RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Marina Biotech Recent Developments and Future Plans

2.9 MiRagen Therapeutics

2.9.1 MiRagen Therapeutics Details

2.9.2 MiRagen Therapeutics Major Business

2.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

2.9.4 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 MiRagen Therapeutics Recent Developments and Future Plans

2.10 Moderna Therapeutics

2.10.1 Moderna Therapeutics Details

2.10.2 Moderna Therapeutics Major Business

2.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

2.10.4 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Moderna Therapeutics Recent Developments and Future Plans

2.11 Quark Pharmaceuticals

2.11.1 Quark Pharmaceuticals Details

2.11.2 Quark Pharmaceuticals Major Business

2.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

2.11.4 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Quark Pharmaceuticals Recent Developments and Future Plans

2.12 Roche

2.12.1 Roche Details

2.12.2 Roche Major Business

2.12.3 Roche RNA-Based Therapeutics and Vaccines Product and Solutions

2.12.4 Roche RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Roche Recent Developments and Future Plans

2.13 Sylentis

2.13.1 Sylentis Details

2.13.2 Sylentis Major Business

2.13.3 Sylentis RNA-Based Therapeutics and Vaccines Product and Solutions

2.13.4 Sylentis RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Sylentis Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global RNA-Based Therapeutics and Vaccines Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 RNA-Based Therapeutics and Vaccines Players Market Share in 2021

3.2.2 Top 10 RNA-Based Therapeutics and Vaccines Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 RNA-Based Therapeutics and Vaccines Players Head Office, Products and Services Provided

3.4 RNA-Based Therapeutics and Vaccines Mergers & Acquisitions

3.5 RNA-Based Therapeutics and Vaccines New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Type (2017-2022)

4.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2017-2022)

5.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2028)

6.2 North America RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2028)

6.3 North America RNA-Based Therapeutics and Vaccines Market Size by Country

6.3.1 North America RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2028)

6.3.2 United States RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

6.3.3 Canada RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

6.3.4 Mexico RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2028)

7.2 Europe RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2028)

7.3 Europe RNA-Based Therapeutics and Vaccines Market Size by Country

7.3.1 Europe RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2028)

7.3.2 Germany RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

7.3.3 France RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

7.3.4 United Kingdom RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

7.3.5 Russia RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

7.3.6 Italy RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2028)

8.2 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2028)

8.3 Asia-Pacific RNA-Based Therapeutics and Vaccines Market Size by Region

8.3.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Region (2017-2028)

8.3.2 China RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8.3.3 Japan RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8.3.4 South Korea RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8.3.5 India RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

8.3.7 Australia RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2028)

9.2 South America RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2028)

9.3 South America RNA-Based Therapeutics and Vaccines Market Size by Country

9.3.1 South America RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2028)

9.3.2 Brazil RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

9.3.3 Argentina RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2028)

10.2 Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2028)

10.3 Middle East & Africa RNA-Based Therapeutics and Vaccines Market Size by Country

10.3.1 Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2028)

10.3.2 Turkey RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

10.3.4 UAE RNA-Based Therapeutics and Vaccines Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global RNA-Based Therapeutics and Vaccines Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global RNA-Based Therapeutics and Vaccines Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market RNA-Based Therapeutics and Vaccines Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global RNA-Based Therapeutics and Vaccines Revenue (USD Million) by Region (2017-2022)

Table 5. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Region (2023-2028)

Table 6. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 7. Alnylam Pharmaceuticals Major Business

Table 8. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

Table 9. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Arbutus Biopharma Corporate Information, Head Office, and Major Competitors

Table 11. Arbutus Biopharma Major Business

Table 12. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product and Solutions

Table 13. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Arrowhead Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 15. Arrowhead Pharmaceuticals Major Business

Table 16. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

Table 17. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. BioNTech Corporate Information, Head Office, and Major Competitors

Table 19. BioNTech Major Business

Table 20. BioNTech RNA-Based Therapeutics and Vaccines Product and Solutions

Table 21. BioNTech RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. CureVac Corporate Information, Head Office, and Major Competitors

Table 23. CureVac Major Business

Table 24. CureVac RNA-Based Therapeutics and Vaccines Product and Solutions

Table 25. CureVac RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Dicerna Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 27. Dicerna Pharmaceuticals Major Business

Table 28. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

Table 29. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Regulus Therapeutics Corporate Information, Head Office, and Major Competitors

Table 31. Regulus Therapeutics Major Business

Table 32. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

Table 33. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Marina Biotech Corporate Information, Head Office, and Major Competitors

Table 35. Marina Biotech Major Business

Table 36. Marina Biotech RNA-Based Therapeutics and Vaccines Product and Solutions

Table 37. Marina Biotech RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. MiRagen Therapeutics Corporate Information, Head Office, and Major Competitors

Table 39. MiRagen Therapeutics Major Business

Table 40. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

Table 41. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Moderna Therapeutics Corporate Information, Head Office, and Major Competitors

Table 43. Moderna Therapeutics Major Business

Table 44. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product and Solutions

Table 45. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Quark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 47. Quark Pharmaceuticals Major Business

Table 48. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product and Solutions

Table 49. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Roche Corporate Information, Head Office, and Major Competitors

Table 51. Roche Major Business

Table 52. Roche RNA-Based Therapeutics and Vaccines Product and Solutions

Table 53. Roche RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Sylentis Corporate Information, Head Office, and Major Competitors

Table 55. Sylentis Major Business

Table 56. Sylentis RNA-Based Therapeutics and Vaccines Product and Solutions

Table 57. Sylentis RNA-Based Therapeutics and Vaccines Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Global RNA-Based Therapeutics and Vaccines Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 59. Global RNA-Based Therapeutics and Vaccines Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 60. Breakdown of RNA-Based Therapeutics and Vaccines by Company Type (Tier 1, Tier 2 and Tier 3)

Table 61. RNA-Based Therapeutics and Vaccines Players Head Office, Products and Services Provided

Table 62. RNA-Based Therapeutics and Vaccines Mergers & Acquisitions in the Past Five Years

Table 63. RNA-Based Therapeutics and Vaccines New Entrants and Expansion Plans

Table 64. Global RNA-Based Therapeutics and Vaccines Revenue (USD Million) by Type (2017-2022)

Table 65. Global RNA-Based Therapeutics and Vaccines Revenue Share by Type (2017-2022)

Table 66. Global RNA-Based Therapeutics and Vaccines Revenue Forecast by Type (2023-2028)

Table 67. Global RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022)

Table 68. Global RNA-Based Therapeutics and Vaccines Revenue Forecast by Application (2023-2028)

Table 69. North America RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2022) & (USD Million)

Table 70. North America RNA-Based Therapeutics and Vaccines Revenue by Type (2023-2028) & (USD Million)

Table 71. North America RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022) & (USD Million)

Table 72. North America RNA-Based Therapeutics and Vaccines Revenue by Application (2023-2028) & (USD Million)

Table 73. North America RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2022) & (USD Million)

Table 74. North America RNA-Based Therapeutics and Vaccines Revenue by Country (2023-2028) & (USD Million)

Table 75. Europe RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2022) & (USD Million)

Table 76. Europe RNA-Based Therapeutics and Vaccines Revenue by Type (2023-2028) & (USD Million)

Table 77. Europe RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022) & (USD Million)

Table 78. Europe RNA-Based Therapeutics and Vaccines Revenue by Application (2023-2028) & (USD Million)

Table 79. Europe RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2022) & (USD Million)

Table 80. Europe RNA-Based Therapeutics and Vaccines Revenue by Country (2023-2028) & (USD Million)

Table 81. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2022) & (USD Million)

Table 82. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Type (2023-2028) & (USD Million)

Table 83. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022) & (USD Million)

Table 84. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Application (2023-2028) & (USD Million)

Table 85. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Region (2017-2022) & (USD Million)

Table 86. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Region (2023-2028) & (USD Million)

Table 87. South America RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2022) & (USD Million)

Table 88. South America RNA-Based Therapeutics and Vaccines Revenue by Type (2023-2028) & (USD Million)

Table 89. South America RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022) & (USD Million)

Table 90. South America RNA-Based Therapeutics and Vaccines Revenue by Application (2023-2028) & (USD Million)

Table 91. South America RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2022) & (USD Million)

Table 92. South America RNA-Based Therapeutics and Vaccines Revenue by Country (2023-2028) & (USD Million)

Table 93. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Type (2017-2022) & (USD Million)

Table 94. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Type (2023-2028) & (USD Million)

Table 95. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Application (2017-2022) & (USD Million)

Table 96. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Application (2023-2028) & (USD Million)

Table 97. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Country (2017-2022) & (USD Million)

Table 98. Middle East & Africa RNA-Based Therapeutics and Vaccines Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. RNA-Based Therapeutics and Vaccines Picture

Figure 2. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Type in 2021

Figure 3. RNA-Based Therapeutics

Figure 4. RNA-Based Vaccines

Figure 5. RNA-Based Therapeutics and Vaccines Revenue Market Share by Application in 2021

Figure 6. Oncology Picture

Figure 7. Immunology Picture

Figure 8. Ophthalmology Picture

Figure 9. Cardiovascular Diseases Picture

Figure 10. Infectious Diseases Picture

Figure 11. Genetic Diseases Picture

Figure 12. Others Picture

Figure 13. Global RNA-Based Therapeutics and Vaccines Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global RNA-Based Therapeutics and Vaccines Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Region (2017-2028)

Figure 16. Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Region in 2021

Figure 17. North America RNA-Based Therapeutics and Vaccines Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe RNA-Based Therapeutics and Vaccines Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America RNA-Based Therapeutics and Vaccines Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. RNA-Based Therapeutics and Vaccines Market Drivers

Figure 23. RNA-Based Therapeutics and Vaccines Market Restraints

Figure 24. RNA-Based Therapeutics and Vaccines Market Trends

Figure 25. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 26. Arbutus Biopharma Recent Developments and Future Plans

Figure 27. Arrowhead Pharmaceuticals Recent Developments and Future Plans

Figure 28. BioNTech Recent Developments and Future Plans

Figure 29. CureVac Recent Developments and Future Plans

Figure 30. Dicerna Pharmaceuticals Recent Developments and Future Plans

Figure 31. Regulus Therapeutics Recent Developments and Future Plans

Figure 32. Marina Biotech Recent Developments and Future Plans

Figure 33. MiRagen Therapeutics Recent Developments and Future Plans

Figure 34. Moderna Therapeutics Recent Developments and Future Plans

Figure 35. Quark Pharmaceuticals Recent Developments and Future Plans

Figure 36. Roche Recent Developments and Future Plans

Figure 37. Sylentis Recent Developments and Future Plans

Figure 38. Global RNA-Based Therapeutics and Vaccines Revenue Share by Players in 2021

Figure 39. RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 40. Global Top 3 Players RNA-Based Therapeutics and Vaccines Revenue Market Share in 2021

Figure 41. Global Top 10 Players RNA-Based Therapeutics and Vaccines Revenue Market Share in 2021

Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 43. Global RNA-Based Therapeutics and Vaccines Revenue Share by Type in 2021

Figure 44. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Type (2023-2028)

Figure 45. Global RNA-Based Therapeutics and Vaccines Revenue Share by Application in 2021

Figure 46. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Application (2023-2028)

Figure 47. North America RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2017-2028)

Figure 48. North America RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2017-2028)

Figure 49. North America RNA-Based Therapeutics and Vaccines Revenue Market Share by Country (2017-2028)

Figure 50. United States RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Canada RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Mexico RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Europe RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2017-2028)

Figure 54. Europe RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2017-2028)

Figure 55. Europe RNA-Based Therapeutics and Vaccines Revenue Market Share by Country (2017-2028)

Figure 56. Germany RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. France RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. United Kingdom RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Russia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Italy RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Asia-Pacific RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2017-2028)

Figure 62. Asia-Pacific RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2017-2028)

Figure 63. Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue Market Share by Region (2017-2028)

Figure 64. China RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Japan RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South Korea RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. India RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Southeast Asia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Australia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. South America RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2017-2028)

Figure 71. South America RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2017-2028)

Figure 72. South America RNA-Based Therapeutics and Vaccines Revenue Market Share by Country (2017-2028)

Figure 73. Brazil RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Argentina RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2017-2028)

Figure 76. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2017-2028)

Figure 77. Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue Market Share by Country (2017-2028)

Figure 78. Turkey RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Saudi Arabia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. UAE RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Methodology

Figure 82. Research Process and Data Source